Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Mirati Therapeutics, Inc. is not a good value stock. Mirati Therapeutics, Inc. is not a good growth stock. Mirati Therapeutics, Inc. is not very popular among insiders. Mirati Therapeutics, Inc. is a mediocre stock to choose.
Log in to see more information.
Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages in developing a pipeli...
News
Mirati Therapeutics ticks higher amid Nasdaq delisting for sale to Bristol-Myers
Seeking Alpha - Healthcare Mirati Therapeutics ticks higher amid Nasdaq delisting for sale to Bristol-Myers...\n more…
Mirati Therapeutics, Inc. (NASDAQ:MRTX) EVP Benjamin Hickey Sells 1,597 Shares of Stock
Ticker Report Mirati Therapeutics, Inc. (NASDAQ:MRTX Get Free Report) EVP Benjamin Hickey sold 1,597 shares of Mirati Therapeutics stock in a transaction that occurred on Tuesday, January 16th. The stock...\n more…
Mirati Therapeutics (NASDAQ:MRTX) Now Covered by Analysts at StockNews.com
Ticker Report StockNews.com initiated coverage on shares of Mirati Therapeutics (NASDAQ:MRTX Free Report) in a research note issued to investors on Sunday. The firm issued a sell rating on the...\n more…